Ansun Biopharma

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Ansun Biopharma sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials 1 currently recruiting 7 completed early-phase tilt upper quartile by trial count

Ansun Biopharma: 8 sponsored US clinical trials, 1 recruiting.

Ansun Biopharma sponsors 8 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 7 completed. 1 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Immunocompromised, with 1 trials.

Upper-quartile sponsor footprint

Ansun Biopharma sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

8 total, page 1 of 1

RECRUITING Phase 3

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

NCT03808922
COMPLETED Phase 2

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen

NCT01644877
COMPLETED Phase 2

An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection

NCT01924793
COMPLETED Phase 2

Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired Influenza

NCT01740063
COMPLETED Phase 1

A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis

NCT01113034
COMPLETED Phase 2

Randomized, Double-blind, Placebo Controlled Phase II Study to Examine the Effects of DAS181 in Healthy Adult Subjects With Laboratory Confirmed Influenza

NCT01037205
COMPLETED Phase 1

DAS181 Single Dose Escalation Study in Healthy Adults

NCT00876161
COMPLETED Phase 1

Single Dose Escalating Study of DAS181 in Adults

NCT00527865

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 4
Phase 3 1

Therapeutic Areas

Immunocompromised 1
Parainfluenza 1
Bronchiectasis 1
Lower Respiratory Tract Infection 1
Asthma 1
COVID-19 1
Healthy 1

What is open in the Ansun Biopharma pipeline

1 recruiting of 8 indexed (13% open); 7 completed (88%).

Phase mix: 1 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: Immunocompromised (1 trial), 6 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Ansun Biopharma: open-pipeline peers nationwide

Peers matched on 8 registered trials and 13% open enrollment, not the therapeutic-area sidebar.

Ansun Biopharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 681012141618 0%10%20%30%40% Total trials Recruiting share Ansun BiopharmaAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Addario Lung Cancer Medical InstituteAmerican UniversityAnnexonAvidity Biosciences
Ansun Biopharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Ansun Biopharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 trials (± recruiting share)

Sponsors near 13% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Ansun Biopharma page

8 registered trials is a research-attention snapshot, not an endorsement of Ansun Biopharma or any single study.

  • 1 of Ansun Biopharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Immunocompromised is the condition Ansun Biopharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Immunocompromised trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Ansun Biopharma pipeline card: 8 registered trials from official public datasets.Report a data error.